Kidney cancer

Robert J. Motzer; Neeraj Agarwal; Clair Beard; Graeme B. Bolger; Barry Boston; Michael A. Carducci; Toni K. Choueiri; Robert A. Figlin; Mayer Fishman; Steven L. Hancock; Gary R. Hudes; Eric Jonasch; Anne Kessinger; Timothy M. Kuzel; Paul H. Lange; Ellis G. Levine; Kim A. Margolin; M. Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G. Redman; Cary N. Robertson; Lawrence H. Schwartz; Joel Sheinfeld; Jue Wang

doi:10.6004/jnccn.2009.0043

Kidney cancer

Robert J. Motzer
, Neeraj Agarwal
, Clair Beard
, Graeme B. Bolger
, Barry Boston
, Michael A. Carducci
, Toni K. Choueiri
, Robert A. Figlin
, Mayer Fishman
, Steven L. Hancock
, Gary R. Hudes
, Eric Jonasch
, Anne Kessinger
, Timothy M. Kuzel
, Paul H. Lange
, Ellis G. Levine
, Kim A. Margolin
, M. Dror Michaelson
, Thomas Olencki
, Roberto Pili

Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, Jue Wang

Medicine

Memorial Sloan-Kettering Cancer Center
University of Utah
Dana-Farber/Brigham and Women's Cancer Center
University of Alabama at Birmingham
St. Jude Children Research Hospital
Johns Hopkins University
City of Hope National Med Center
Moffitt Cancer Center
Stanford University
Fox Chase Cancer Center
University of Texas MD Anderson Cancer Center
Nebraska Medicine
Northwestern University
Fred Hutchinson Cancer Research Center
Roswell Park Cancer Institute
Massachusetts General Hospital Cancer Center
Ohio State University
University of Michigan, Ann Arbor
Duke University

Research output: Contribution to journal › Review article › peer-review

183 Scopus citations

Abstract

In 2008, an estimated 54,390 Americans were diagnosed with and 13,010 died of kidney cancer in the United States. The rate of renal cell carcinoma (RCC) has increased 2% per year for the past 65 years. Smoking and obesity are among the risk factors for RCC development, with tumor grade, local extent of the tumor, presence of regional nodal metastases, and evidence of metastatic disease at presentation the most important prognostic determinants of 5-year survival. These guidelines discuss evaluation, staging, treatment, and management after treatment. Important updates for 2009 include the addition of everolimus as second-line therapy after a tyrosine kinase inhibitor and the change to a category 1 recommendation for bevaciumab and interferon for first-line therapy for clear cell histologies.

Original language	English
Pages (from-to)	618-630
Number of pages	13
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	7
Issue number	6
DOIs	https://doi.org/10.6004/jnccn.2009.0043
State	Published - Jun 2009

Keywords

Clear cell tumors
Kidney disease
NCCN Clinical Practice Guidelines
Nephrectomy
Renal cell carcinoma

Access to Document

10.6004/jnccn.2009.0043

Cite this

Motzer, R. J., Agarwal, N., Beard, C., Bolger, G. B., Boston, B., Carducci, M. A., Choueiri, T. K., Figlin, R. A., Fishman, M., Hancock, S. L., Hudes, G. R., Jonasch, E., Kessinger, A., Kuzel, T. M., Lange, P. H., Levine, E. G., Margolin, K. A., Michaelson, M. D., Olencki, T., ... Wang, J. (2009). Kidney cancer. JNCCN Journal of the National Comprehensive Cancer Network, 7(6), 618-630. https://doi.org/10.6004/jnccn.2009.0043

@article{520f0617e31d409999e2dec5b7cd8162,

title = "Kidney cancer",

abstract = "In 2008, an estimated 54,390 Americans were diagnosed with and 13,010 died of kidney cancer in the United States. The rate of renal cell carcinoma (RCC) has increased 2\% per year for the past 65 years. Smoking and obesity are among the risk factors for RCC development, with tumor grade, local extent of the tumor, presence of regional nodal metastases, and evidence of metastatic disease at presentation the most important prognostic determinants of 5-year survival. These guidelines discuss evaluation, staging, treatment, and management after treatment. Important updates for 2009 include the addition of everolimus as second-line therapy after a tyrosine kinase inhibitor and the change to a category 1 recommendation for bevaciumab and interferon for first-line therapy for clear cell histologies.",

keywords = "Clear cell tumors, Kidney disease, NCCN Clinical Practice Guidelines, Nephrectomy, Renal cell carcinoma",

author = "Motzer, \{Robert J.\} and Neeraj Agarwal and Clair Beard and Bolger, \{Graeme B.\} and Barry Boston and Carducci, \{Michael A.\} and Choueiri, \{Toni K.\} and Figlin, \{Robert A.\} and Mayer Fishman and Hancock, \{Steven L.\} and Hudes, \{Gary R.\} and Eric Jonasch and Anne Kessinger and Kuzel, \{Timothy M.\} and Lange, \{Paul H.\} and Levine, \{Ellis G.\} and Margolin, \{Kim A.\} and Michaelson, \{M. Dror\} and Thomas Olencki and Roberto Pili and Redman, \{Bruce G.\} and Robertson, \{Cary N.\} and Schwartz, \{Lawrence H.\} and Joel Sheinfeld and Jue Wang",

year = "2009",

month = jun,

doi = "10.6004/jnccn.2009.0043",

language = "English",

volume = "7",

pages = "618--630",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "6",

}

Motzer, RJ, Agarwal, N, Beard, C, Bolger, GB, Boston, B, Carducci, MA, Choueiri, TK, Figlin, RA, Fishman, M, Hancock, SL, Hudes, GR, Jonasch, E, Kessinger, A, Kuzel, TM, Lange, PH, Levine, EG, Margolin, KA, Michaelson, MD, Olencki, T, Pili, R, Redman, BG, Robertson, CN, Schwartz, LH, Sheinfeld, J & Wang, J 2009, 'Kidney cancer', JNCCN Journal of the National Comprehensive Cancer Network, vol. 7, no. 6, pp. 618-630. https://doi.org/10.6004/jnccn.2009.0043

TY - JOUR

T1 - Kidney cancer

AU - Motzer, Robert J.

AU - Agarwal, Neeraj

AU - Beard, Clair

AU - Bolger, Graeme B.

AU - Boston, Barry

AU - Carducci, Michael A.

AU - Choueiri, Toni K.

AU - Figlin, Robert A.

AU - Fishman, Mayer

AU - Hancock, Steven L.

AU - Hudes, Gary R.

AU - Jonasch, Eric

AU - Kessinger, Anne

AU - Kuzel, Timothy M.

AU - Lange, Paul H.

AU - Levine, Ellis G.

AU - Margolin, Kim A.

AU - Michaelson, M. Dror

AU - Olencki, Thomas

AU - Pili, Roberto

AU - Redman, Bruce G.

AU - Robertson, Cary N.

AU - Schwartz, Lawrence H.

AU - Sheinfeld, Joel

AU - Wang, Jue

PY - 2009/6

Y1 - 2009/6

N2 - In 2008, an estimated 54,390 Americans were diagnosed with and 13,010 died of kidney cancer in the United States. The rate of renal cell carcinoma (RCC) has increased 2% per year for the past 65 years. Smoking and obesity are among the risk factors for RCC development, with tumor grade, local extent of the tumor, presence of regional nodal metastases, and evidence of metastatic disease at presentation the most important prognostic determinants of 5-year survival. These guidelines discuss evaluation, staging, treatment, and management after treatment. Important updates for 2009 include the addition of everolimus as second-line therapy after a tyrosine kinase inhibitor and the change to a category 1 recommendation for bevaciumab and interferon for first-line therapy for clear cell histologies.

AB - In 2008, an estimated 54,390 Americans were diagnosed with and 13,010 died of kidney cancer in the United States. The rate of renal cell carcinoma (RCC) has increased 2% per year for the past 65 years. Smoking and obesity are among the risk factors for RCC development, with tumor grade, local extent of the tumor, presence of regional nodal metastases, and evidence of metastatic disease at presentation the most important prognostic determinants of 5-year survival. These guidelines discuss evaluation, staging, treatment, and management after treatment. Important updates for 2009 include the addition of everolimus as second-line therapy after a tyrosine kinase inhibitor and the change to a category 1 recommendation for bevaciumab and interferon for first-line therapy for clear cell histologies.

KW - Clear cell tumors

KW - Kidney disease

KW - NCCN Clinical Practice Guidelines

KW - Nephrectomy

KW - Renal cell carcinoma

UR - https://www.scopus.com/pages/publications/67651214070

U2 - 10.6004/jnccn.2009.0043

DO - 10.6004/jnccn.2009.0043

M3 - Review article

C2 - 19555584

AN - SCOPUS:67651214070

SN - 1540-1405

VL - 7

SP - 618

EP - 630

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 6

ER -

Kidney cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this